Medi-Maa

Macrosalb, the active ingredient in Medi-Maa, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to visualize physiological processes in various organ systems. GNH USA supplies Medi-Maa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Medi-Maa is used in nuclear medicine imaging to assess functional activity of target organs. Oncologic imaging: assists in tumor detection, staging and treatment monitoring. Cardiac perfusion imaging: evaluates myocardial blood flow and viability. Neurological imaging: helps assess cerebral metabolism and detect focal lesions.

Medi-Maa may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Headache - Dizziness or light‑headedness - Transient flushing - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic reaction or severe allergy - Significant hypotension requiring intervention - Radiation‑induced skin injury at the injection site - Renal toxicity in patients with impaired function - Hematologic abnormalities such as thrombocytopenia - Severe arrhythmias in susceptible individuals

Before using Medi-Maa, consider the following safety measures. - Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: discontinue nursing for an appropriate period after administration. - Renal function: assess and adjust use in patients with severe impairment. - Known allergy: screen for hypersensitivity to technetium‑99m or excipients. - Concurrent radiopharmaceuticals: avoid overlapping studies to limit cumulative radiation dose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medi-Maa may interact with other agents that influence radiation exposure or physiological responses.

Major Interactions (Avoid): - Concurrent administration of other radiopharmaceuticals: additive radiation dose. - Iodinated contrast agents used shortly before or after: may interfere with image quality. - Myelosuppressive chemotherapy: increased risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypotensive reactions. - Antihistamines: could diminish signs of an allergic response. - Diuretics: may alter renal clearance of the tracer.